^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Excerpt:
FGFR2 has been found to be amplified and overexpressed in the colon cancer cell line H716 (13). We found that ponatinib potently inhibited the growth of H716 cells with a GI50 value of 7 nmol/L but did not affect the growth of Colo205 cells (430 nmol/L; Fig. 5D) that lack constitutive FGFR2 phosphorylation...
DOI:
10.1158/1535-7163.MCT-11-0450